Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

58.29USD
3:59pm EST
Change (% chg)

$1.18 (+2.07%)
Prev Close
$57.11
Open
$56.97
Day's High
$58.43
Day's Low
$55.51
Volume
592,302
Avg. Vol
724,667
52-wk High
$59.74
52-wk Low
$11.57

CLVS.OQ

Chart for CLVS.OQ

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth... (more)

Overall

Beta: 1.92
Market Cap(Mil.): $2,531.84
Shares Outstanding(Mil.): 44.33
Dividend: --
Yield (%): --

Financials

  CLVS.OQ Industry Sector
P/E (TTM): -- 44.51 30.50
EPS (TTM): -10.36 -- --
ROI: -68.89 -1.38 14.85
ROE: -168.85 -1.00 16.27

BRIEF-Millennium Management reports 5.1 pct passive stake in Clovis Oncology

* Millennium Management Llc reports 5.1 percent passive stake in Clovis Oncology Inc as of Jan 6, 2017 - Sec filing Source: (http://bit.ly/2iHJ0N2) Further company coverage:

Jan 11 2017

Clovis's ovarian cancer drug wins accelerated FDA approval

The U.S. Food and Drug Administration granted accelerated approval to Clovis Oncology Inc's ovarian cancer drug in patients with a specific gene mutation whose disease had advanced despite two or more rounds of chemotherapy.

Dec 19 2016

BRIEF-Clovis Oncology announces Rucaparib data presentations at ESMO 2016 Congress

* Clovis Oncology announces Rucaparib data presentations at ESMO 2016 Congress

Sep 28 2016

Clovis short sellers undaunted as stock price surges

NEW YORK Clovis Oncology Inc's share price has doubled in the past month, fueled by positive developments for the company's experimental cancer drug and takeover speculation. But some investors also appear to be increasing bets against the stock.

Sep 26 2016

Clovis short sellers undaunted as stock price surges

NEW YORK, Sept 26 Clovis Oncology Inc's share price has doubled in the past month, fueled by positive developments for the company's experimental cancer drug and takeover speculation. But some investors also appear to be increasing bets against the stock.

Sep 26 2016

BRIEF-Clovis Oncology -FDA has notified it is not currently planning to hold advisory committee meeting to discuss for Rucaparib

* FDA has notified co that FDA is not currently planning to hold advisory committee meeting to discuss NDA for Rucaparib Source text: [http://bit.ly/2c9EYtK] Further company coverage:

Sep 08 2016

BRIEF-Clovis enters into first amendment to license agreement between Clovis and pfizer

* Entered into first amendment to license agreement between Clovis and Pfizer, Inc.

Aug 30 2016

BRIEF-Clovis Oncology says FDA accepts co's new drug application for rucaparib for priority review

* FDA accepts Clovis Oncology's new drug application for rucaparib for priority review for the treatment of advanced mutant BRCA ovarian cancer

Aug 23 2016

BRIEF-Clovis Oncology Q2 adjusted loss per share $2.07 excluding items

* Clovis oncology announces q2 2016 operating results and corporate update

Aug 08 2016

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,476 +31.00
Pfizer Inc. (PFE.N) $31.77 +0.07
AstraZeneca plc (AZN.L) 4,318.50 -150.00
BioMarin Pharmaceutical Inc. (BMRN.OQ) $84.62 -1.53
TESARO Inc (TSRO.OQ) $147.00 -2.91
AbbVie Inc (ABBV.N) $61.15 -0.23
Novartis AG (NOVN.S) CHF70.90 -0.20
Johnson & Johnson (JNJ.N) $114.15 -0.05
Eli Lilly and Co (LLY.N) $76.81 -0.03
GlaxoSmithKline plc (GSK.L) 1,546.50 -6.50

Earnings vs. Estimates